- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00294372
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
Randomised, Double-blind, Placebo-controlled 7 Day Monotherapy Phase IIa Study to Evaluate the Antiviral Activity and Safety of Increasing Doses of Oral Administered RTV-boosted BILR 355 BS (75 mg and 150 mg Twice Daily) in HIV-1-infected, NNRTI-experienced Patients, Followed by 28 Day Combination Therapy With Tipranavir or Lopinavir Based HAART-regimen
연구 개요
연구 유형
등록
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Berlin, 독일
- Boehringer Ingelheim Investigational Site
-
Bochum, 독일
- Boehringer Ingelheim Investigational Site
-
Bonn, 독일
- Boehringer Ingelheim Investigational Site
-
Erlangen, 독일
- Boehringer Ingelheim Investigational Site
-
Frankfurt/Main, 독일
- Boehringer Ingelheim Investigational Site
-
Hamburg, 독일
- Boehringer Ingelheim Investigational Site
-
Hannover, 독일
- Boehringer Ingelheim Investigational Site
-
Heidelberg, 독일
- Boehringer Ingelheim Investigational Site
-
Mainz, 독일
- Boehringer Ingelheim Investigational Site
-
Munchen, 독일
- Boehringer Ingelheim Investigational Site
-
Ulm, 독일
- Boehringer Ingelheim Investigational Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Signed informed consent in accordance with GCP and local regulatory requirements prior to trial participation.
- HIV-1 infected males or females >= 18 years of age.
- History of NNRTI based HAART >= 8 weeks and at least one, but not more than 3 NNRTI-associated resistance mutations by current genotype
- TPV/r or LPV/r susceptible
- CD4+ T lymphocyte count >= 100 cells/?l.
7. HIV-1 viral load >= 2000 copies/mL at screening. 8. Karnofsky score >= 70 9. Based on the antiviral resistance profile of the patients virus, the investigator must be able to construct a background HAART treatment regimen (OBR) such that the patient will receive 3 effective ARV drugs, in addition to his study medication.
10. Acceptable screening laboratory values (Visit 1) that indicate adequate baseline organ function. Laboratory values are considered to be acceptable if the following apply: Absolute neutrophil count (ANC) >750/mm3 Hemoglobin >= 10 g/dL Platelet count >99,000/mm3 AST, ALT , and alkaline phosphatase < 2.5xULN >= DAIDS Grade 1) Total bilirubin <2.5xULN Serum amylase <1.5xULN 11. Acceptable medical history, as assessed by the investigator, with chest x-ray results and ECG within 1 year of study participation.
12. Willingness to abstain from ingesting substances which may alter plasma study drug levels by interaction with the cytochrome P450 system 13. A prior AIDS defining event, excluding mycobacterial and invasive fungal infections, is acceptable as long as it has resolved or the subject has been on stable treatment (e.g. opportunistic infection) for at least 12 weeks before screening (Visit 1). Note that prior oral thrush, candida esophagitis and cutaneous candida is acceptable.
Exclusion Criteria:
- The following resistance mutations demonstrated at any time prior to starting trial therapy: V106A and/or Y188L
Female patients of child-bearing potential who:
have a positive serum pregnancy test at screening or during the study, are breast feeding, are planning to become pregnant, are not willing to use a barrier method of contraception.
- Active Hepatitis B or C disease defined as HBsAg positive or HCV RNA positive with AST/ALT > DAIDS Grade 1
- Acute/previous mycobacterial or invasive fungal infection requiring therapy or prophylaxis with drugs interfering with or significantly affected by the cytochrome P450 system
- Use of investigational medications within 30 days before study entry or during the trial.
- Use of concomitant drugs that may significantly reduce plasma levels of the study medications.
- Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g. interferon, cyclosporin, hydroxyurea, interleukin 2).
- Patients currently treated with systemic ant-cancer chemotherapy
- Inability to adhere to the requirements of the protocol, including active substance abuse, as defined by the investigator.
- In the opinion of the investigator, likely survival of less than 12 months because of underlying disease.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
The primary endpoint will be reduction in plasma HIV-1 RNA from baseline to day 8, expressed in log10 copies/mm3.
기간: day 8
|
day 8
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Virologic response at Day 8 and Day 35 using <400 copies/mL and 0.5, 1 and 1.5 log10 reduction in viral load from baseline
기간: up to week 5
|
up to week 5
|
Change from baseline in viral load at each visit
기간: up to week 9
|
up to week 9
|
Change from baseline in CD4+ cell counts at each visit
기간: up to week 9
|
up to week 9
|
Time averaged change from baseline in viral load through Days 8 and 35
기간: up to week 5
|
up to week 5
|
Number of reverse transcriptase (RT) mutations at baseline
기간: up to week 5
|
up to week 5
|
Number of NNRTI resistance-associated mutations at baseline (refer to Appendix 10.4)
기간: up to week 5
|
up to week 5
|
The presence of specific RT mutations (both in the list of NNRTI mutations and not in the list for exploratory purposes) at baseline
기간: up to week 5
|
up to week 5
|
The inhibitory quotient and minimum measured concentration of the analyte in plasma (Cmin)
기간: up to Day 8
|
up to Day 8
|
Exploration of mutations that emerge with exposure to BILR 355 BS to determine the effect on both viral load and IC50 fold change from reference
기간: up to week 5
|
up to week 5
|
Area under the concentration-time curve of the analyte in plasma over the time interval 0 to 12 hours post-dose (AUC0-12h)
기간: up to week 5
|
up to week 5
|
Maximum measured concentration of the analyte in plasma (Cmax)
기간: up to week 5
|
up to week 5
|
Changes in total cholesterol, LDL, HDL and triglycerides from baseline to days 8 and 35
기간: up to week 9
|
up to week 9
|
Incidence of rash, hepatic events, and CNS adverse events
기간: up to week 9
|
up to week 9
|
Incidence of any adverse events (treatment related and unrelated)
기간: up to week 9
|
up to week 9
|
Incidence of laboratory test abnormalities
기간: up to week 9
|
up to week 9
|
Incidence of serious adverse events (including AIDS-defining events)
기간: up to week 9
|
up to week 9
|
Incidence of ≥ DAIDS 2 Grade elevation in ALT/AST
기간: up to week 9
|
up to week 9
|
Incidence of AEs leading to discontinuation from the study
기간: up to week 9
|
up to week 9
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HIV 감염에 대한 임상 시험
-
Hospital Clinic of Barcelona완전한
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS Foundation완전한파트너 HIV 테스트 | 부부 에이즈 상담 | 커플커뮤니케이션 | HIV 발병률카메룬, 도미니카 공화국, 그루지야, 인도
-
University of Minnesota빼는HIV 감염 | HIV/에이즈 | 에이즈 | 보조기구 | 에이즈/HIV 문제 | 에이즈와 감염미국
-
Michael HoelscherClinton Health Access Initiative Inc.; Instituto Nacional de Saúde (INS), Ministério da... 그리고 다른 협력자들모집하지 않고 적극적으로HIV, 신생아 HIV 조기 진단(EID), 현장 진료 검사(PoC)모잠비크, 탄자니아
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)완전한
-
Erasmus Medical Center모병
-
Allegheny Singer Research Institute (also known...모집하지 않고 적극적으로
-
Erasmus Medical Center아직 모집하지 않음
-
University of Maryland, BaltimoreNational Institute of Mental Health (NIMH); Albert Einstein College of Medicine; Yale University 그리고 다른 협력자들아직 모집하지 않음HIV 예방 | HIV 사전 노출 예방
-
Erasmus Medical Center모집하지 않고 적극적으로
위약에 대한 임상 시험
-
Assistance Publique - Hôpitaux de Paris아직 모집하지 않음
-
University Hospital, Strasbourg, France모집하지 않고 적극적으로
-
AJU Pharm Co., Ltd.OM Pharma SA모병